1
|
Ricci FS, D’Alessandro R, Somà A, Salvalaggio A, Rossi F, Rampone S, Gamberini G, Davico C, Peretta P, Cacciacarne M, Gaglini P, Pacca P, Pilloni G, Ragazzi P, Bertin D, Vallero SG, Fagioli F, Vitiello B. Development and application of a diagnostic and severity scale to grade post-operative pediatric cerebellar mutism syndrome. Eur J Pediatr 2022; 181:941-950. [PMID: 34651204 PMCID: PMC8897365 DOI: 10.1007/s00431-021-04290-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2021] [Revised: 10/03/2021] [Accepted: 10/04/2021] [Indexed: 11/24/2022]
Abstract
The post-operative pediatric cerebellar mutism syndrome (CMS) affects about one-third of children and adolescents following surgical removal of a posterior fossa tumor (PFT). According to the Posterior Fossa Society consensus working definition, CMS is characterized by delayed-onset mutism/reduced speech and emotional lability after cerebellar or 4th ventricle tumor surgery in children, and is frequently accompanied by additional features such as hypotonia and oropharyngeal dysfunction/dysphagia. The main objective of this work was to develop a diagnostic scale to grade CMS duration and severity. Thirty consecutively referred subjects, aged 1-17 years (median 8 years, IQR 3-10), were evaluated with the proposed Post-Operative Pediatric CMS Survey after surgical resection of a PFT and, in case of CMS, for 30 days after the onset (T0) or until symptom remission. At day 30 (T1), CMS was classified into mild, moderate, or severe according to the proposed scale. CMS occurred in 13 patients (43%, 95% C.I.: 25.5-62.6%), with mild severity in 4 cases (31%), moderate in 4 (31%), and severe in 5 (38%). At T1, longer symptom persistence was associated with greater severity (p = 0.01). Greater severity at T0 predicted greater severity at T1 (p = 0.0001). Children with a midline tumor location and those aged under 5 years at diagnosis were at higher risk of CMS (p = 0.025 and p = 0.008, respectively). In conclusion, the proposed scale is a simple and applicable tool for estimating the severity of CMS at its onset, monitoring its course over time, and providing an early prognostic stratification to guide treatment decisions.
Collapse
Affiliation(s)
- Federica S. Ricci
- grid.7605.40000 0001 2336 6580Section of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy ,Section of Child and Adolescent Neuropsychiatry, Children’s Hospital “Regina Margherita”, Piazza Polonia 94, 10126 Torino, Italy
| | - Rossella D’Alessandro
- grid.7605.40000 0001 2336 6580Section of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy
| | - Alessandra Somà
- grid.7605.40000 0001 2336 6580Section of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy
| | - Anna Salvalaggio
- grid.7605.40000 0001 2336 6580Section of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy
| | - Francesca Rossi
- grid.7605.40000 0001 2336 6580Section of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy
| | - Sara Rampone
- Child and Adolescent Neuropsychiatry Unit, Arrigo Hospital, Alessandria, Italy
| | - Giorgia Gamberini
- grid.7605.40000 0001 2336 6580Section of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy
| | - Chiara Davico
- grid.7605.40000 0001 2336 6580Section of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy
| | - Paola Peretta
- Section of Pediatric Neurosurgery, Children’s Hospital “Regina Margherita”, Torino, Italy
| | - Mario Cacciacarne
- Section of Pediatric Neurosurgery, Children’s Hospital “Regina Margherita”, Torino, Italy
| | - Pierpaolo Gaglini
- Section of Pediatric Neurosurgery, Children’s Hospital “Regina Margherita”, Torino, Italy
| | - Paolo Pacca
- Section of Pediatric Neurosurgery, Children’s Hospital “Regina Margherita”, Torino, Italy
| | - Giulia Pilloni
- Section of Pediatric Neurosurgery, Children’s Hospital “Regina Margherita”, Torino, Italy
| | - Paola Ragazzi
- Section of Pediatric Neurosurgery, Children’s Hospital “Regina Margherita”, Torino, Italy
| | - Daniele Bertin
- grid.7605.40000 0001 2336 6580Section of Pediatric Onco-Hematology, Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy
| | - Stefano G. Vallero
- grid.7605.40000 0001 2336 6580Section of Pediatric Onco-Hematology, Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy
| | - Franca Fagioli
- grid.7605.40000 0001 2336 6580Section of Pediatric Onco-Hematology, Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy
| | - Benedetto Vitiello
- grid.7605.40000 0001 2336 6580Section of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy
| |
Collapse
|